Biochemical markers of bone formation in the study of postmenopausal osteoporosis

Cabrera, Casimira Domínguez; Henríquez, M. Sosa; Traba, M. L.; Villafañe, E. Alvarez; Piedra, Concepción de la

doi:10.1007/bf02672511

Cited by 43 publications

(9 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pino et al [12] found that osteocalcin is a promising marker of bone turnover useful in the diagnosis and follow-up of high turnover osteoporosis. Similar observations were reported by a number of other studies Verit et al [13], Cabrera et al [14] and Rosenquist et al [15]. Table 1 shows significant decrease in osteocalcin level from baseline to post therapy of 3 months (Alendronate ?…”

Section: Resultssupporting

confidence: 89%

BMD and Serum Intact Osteocalcin in Postmenopausal Osteoporosis Women

2010

View full text Add to dashboard Cite

India seems to have the highest prevalence of osteoporosis. With growing awareness of osteoporosis and its impact on life span especially in India, special attention is being paid to early detection, management and treatment of postmenopausal osteoporosis in women. Measurement of BMD and osteocalcin are of value in estimating bone turnover rates. The aim of this study is (1) to measure the specific, sensitive bone formation marker such as osteocalcin and BMD in postmenopausal osteoporosis women and postmenopausal non-osteoporosis women; (2) the follow up study to evaluate the impact of specific antiresorptive therapy (alendronate ? calcium ? vitamin D) regimen in postmenopausal osteoporosis by assaying osteocalcin and BMD. Sixty clinically diagnosed postmenopausal osteoporosis patients and 60 normal subjects (postmenopausal non-osteoporosis women) were recruited as control. Mean bone mineral density T score and Z score was significantly decreased (P \ 0.001) in postmenopausal osteoporosis patients as compared to controls. Highly significant increase in the mean score of BMD-T score and Z score from baseline to post therapy of 3 months was observed in postmenopausal osteoporosis women. Serum osteocalcin levels were significantly increased (P \ 0.001) as compared to control group. Serum osteocalcin levels were decreased significantly (P \ 0.001) from baseline to post therapy of 3 months in postmenopausal osteoporosis women. BMD is the best quantifiable predictor of osteoporotic fracture and osteocalcin is specific, sensitive, promising, currently used marker for better prognosis of osteoporosis and for monitoring responses to antiresorptive therapy.

show abstract

Section: Resultssupporting

confidence: 89%

BMD and Serum Intact Osteocalcin in Postmenopausal Osteoporosis Women

2010

View full text Add to dashboard Cite

show abstract

“…Moreover, in the present study when women were stratified into normal, osteopenic and osteoporotic groups, s-CTX levels were significantly higher in women with spine or femur BMD in the osteoporotic range than in normal or osteopenic women. This finding is in accordance with the observation of Dominguez Cabrera et al 17 and is likely to be linked to an increased bone resorption that occurs in women with osteoporosis and, therefore, is mainly evident in this group of women. But the data around the correlation lines were highly scattered for s-CTX (as well as for BAP and OC), indicating the presence of a considerable interindividual variability.…”

Section: Discussionsupporting

confidence: 93%

Role of type I collagen C telopeptide, bone‐specific alkaline phosphatase and osteocalcin in the assessment of bone status in postmenopausal women

Trento¹,

Pietropolli²,

Ticconi³

et al. 2009

J of Obstet and Gynaecol

View full text Add to dashboard Cite

show abstract

“…The finding that PICP and PINP levels were lower in the osteoporotic women than in the early menopausal women is discordant with the results of Dominguez Cabrera et al [24] who found higher levels of these two markers of bone collagen formation in a group of osteoporotic women than in healthy menopausal women. This conflicting point is of interest and deserves further studies as our results suggest a negative balance in collagen turnover in osteoporosis.…”

Section: Discussionsupporting

confidence: 74%

Differences in the Capacity of Several Biochemical Bone Markers to Assess High Bone Turnover in Early Menopause and Response to Alendronate Therapy

Fink

Cormier

Steinmetz³

et al. 2000

Osteoporos Int

View full text Add to dashboard Cite

We measured bone mineral density (BMD), four markers of bone formation [bone alkaline phosphatase (bAP), osteocalcin (Oc), N- and C-terminal propeptide of type I procollagen (PINP and PICP respectively)] and five markers of bone resorption [serum C-terminal telopeptide of type I collagen (CTx), urinary CTx, N-terminal cross-linked telopeptide (NTx), free and total deoxypyridinoline (fDpd and tDpd respectively)] in 28 healthy premenopausal women (45.7 +/- 3.0 years), 15 early (< 7 years) healthy menopausal women (53.8 +/- 3.1 years) and 20 osteoporotic women (65.3 +/- 8.2 years). Bone markers and BMD were also measured in the osteoporotic women 4.1 +/- 0.2 and 12.6 +/- 1.2 months after the beginning of alendronate therapy (Fosamax, 10 mg/day) respectively (BMD in 16/20). We calculated the intra-individual coefficient of variation (iCV) and the least significant change (LSC) for each bone marker from a subset of 9 healthy premenopausal women (32 +/- 5 years) who had a first and a second morning void urine collection (FMV and SMV respectively) and a blood sample on 4 nonconsecutive days (mean interval 14 +/- 3 days). None of the bone markers was correlated with BMD (except p = 0.043 between serum Oc and hip BMD). All markers, except fDpd, were increased significantly in early menopausal women when compared with the premenopausal group. Serum CTx presented the highest increase at menopause (+67.8%) and identified the highest rate (11/15) of early menopausal women with bone turnover above the premenopausal range. The iCVs for bone formation markers (7.2-14.4%) were lower than those for bone resorption markers (14.6-22.3%). The iCVs obtained on FMV and SMV were not different. The decrease after 4 months of alendronate was significant for each bone marker but variable from one marker to another. Serum CTx showed the largest decrease (70.8%) and identified the highest number of biologically responding patients (change > LSC; n = 17/20). A significant change in serum CTx after 4 months of alendronate was the best predictor of a significant gain in spine BMD (i.e., > or = 27 mg/cm2) after 1 year of therapy, allowing 15 of 16 patients (94%) to be classified correctly (one false-positive). Urinary NTx/Cr was the second best predictor. Despite a moderately high iCV (20.6%), serum CTx appeared the most effective of the markers tested and could be of interest for the detection of high bone turnover and the longitudinal monitoring of alendronate therapy in the individual patient. It must be stressed that serum PINP and urinary NTx and tDpd compared very similarly with serum CTx for monitoring alendronate therapy.

show abstract

Biochemical markers of bone formation in the study of postmenopausal osteoporosis

Cited by 43 publications

References 16 publications

BMD and Serum Intact Osteocalcin in Postmenopausal Osteoporosis Women

BMD and Serum Intact Osteocalcin in Postmenopausal Osteoporosis Women

Role of type I collagen C telopeptide, bone‐specific alkaline phosphatase and osteocalcin in the assessment of bone status in postmenopausal women

Differences in the Capacity of Several Biochemical Bone Markers to Assess High Bone Turnover in Early Menopause and Response to Alendronate Therapy

Contact Info

Product

Resources

About